中国神经再生研究(英文版) ›› 2023, Vol. 18 ›› Issue (9): 1881-1883.doi: 10.4103/1673-5374.367927

• 综述:脑损伤修复保护与再生 • 上一篇    下一篇

间充质干细胞用于COVID-19相关脑卒中的治疗

  

  • 出版日期:2023-09-15 发布日期:2023-03-06

Use of mesenchymal stem cell therapy in COVID-19 related strokes

Mahika Rawat, Chiao Ng, Emaad Khan, Rayyan A. Shah, Suha Ashfaq, Ghaith A. Bahader, Zahoor A. Shah*   

  1. Department of Medicinal and Biological Chemistry, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA
  • Online:2023-09-15 Published:2023-03-06
  • Contact: Zahoor A. Shah, PhD, zahoor.shah@utoledo.edu.

摘要: https://orcid.org/0000-0001-8977-1618 (Zahoor A. Shah) 

Abstract: Coronavirus disease 2019 (COVID-19) has affected a broad demographics, eliciting a more significant effect on specific groups such as males, African Americans, and Hispanic minorities. Treatment of COVID-19 often requires antiviral drugs or monoclonal antibodies. However, immunotherapies such as mesenchymal stem cells and mesenchymal stem cells-derived exosomal vesicles should be evaluated as treatment options for COVID-19. Mesenchymal stem cell therapy offers regenerative, anti-inflammatory, and immunomodulatory properties that can speed up the recovery from COVID-19. Mesenchymal stem cell therapy can also benefit COVID-19 patients who suffer from strokes, as COVID-19 increases the risk of strokes due to increased cytokines and clotting factors. Most stroke cases that occur in COVID-19 patients are ischemic strokes. Therefore, with the help of mesenchymal stem cell therapy and mesenchymal stem cells-derived exosomes, COVID-19-induced stroke patients might benefit from dual-ended treatment. The objective of this review was to discuss COVID-19 and stroke incidence and the available treatment options.

Key words: COVID-19, cytokines, immunotherapy, interleukin-7, mesenchymal stem cells, neuroinflammation, sex differences, stroke